|
Oct 16
|
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
|
|
Mar 27
|
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
|
|
Mar 27
|
BLRX: First Aphexda Sales Recognized
|
|
Mar 26
|
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
|
|
Dec 21
|
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
|
|
Nov 20
|
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
|
|
Sep 11
|
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma
|
|
Sep 5
|
BLRX: On Your Marks, Get Set…
|